Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / AFMD - Affimed receives approval to begin human trial for acute myeloid leukemia therapy in France

AFMD - Affimed receives approval to begin human trial for acute myeloid leukemia therapy in France

Affimed N.V.

  • Affimed N.V. ( NASDAQ: AFMD )  is trading 2.5% higher premarket after it said on Thursday the French National Agency for the Safety of Medicines and Health Products had approved a clinical trial application for the phase 1 study of AFM28 in relapsed/refractory acute myeloid leukemia.
  • The company has filed applications to begin trial for AFM28-101 in other European jurisdictions as well, and additional applications are planned for submission in early 2023.
  • ( AFMD ) also plans to investigate AFM28 in combination with allogenic natural killer (NK) cell therapy

For further details see:

Affimed receives approval to begin human trial for acute myeloid leukemia therapy in France
Stock Information
Company Name: Affimed N.V.
Stock Symbol: AFMD
Market: NASDAQ
Website: affimed.com
Menu
AFMD AFMD Quote AFMD Short AFMD News AFMD Articles AFMD Message Board
Get AFMD Alerts

News, Short Squeeze, Breakout and More Instantly...